SUPPLEMENTAL MATERIAL

Minimal clinically important differences in average, best, worst and current intensity and unpleasantness of chronic breathlessness

Table S1. Minimal clinically important differences (MCIDs) calculated by anchor-based methods for all participants

Table S2. Minimal clinically important differences (MCIDs) in participants with mMRC 3-4

Table S3. Relative MCIDs (percentage change from baseline) calculated using two participant anchors

Table S1. Minimal clinically important differences (MCIDs) calculated by anchor-based methods for all participants

Dimension		Unpleasantness	Intensity			
Focal period		**Current**	**Current**	**Average**	**Best**	**Worst**
Participant preference question used						
I have been less breathless during the past week	Yes (n/N)	119/229	121/231	124/235	123/234	124/235
	Mean Changes from baseline (SD)	-7.3 (26.1)	-12.7 (23.5)	-8.1 (18.1)	-7.3 (19.5)	-11.9 (27.7)
	No (n/N)	110/229	110/231	111/235	111/234	111/235
	Mean Change from baseline (SD)	3.6 (20.9)	1.2 (21.3)	1.4 (20.1)	5.1 (20.8)	-1.0 (24.4)
	MCID (95% CI)	-10.9 (-17.1, -4.7)	-13.9 (-19.7, -8.1)	-9.5 (-14.4, -4.6)	-12.4 (-17.6, -7.2)	-10.9 (-17.6, -4.2)
This medication would benefit me enough to be on it long term	Yes (n/N)	111/223	112/225	113/229	112/228	113/229
	Mean Changes from baseline (SD)	-7.3 (23.4)	-11.0 (22.5)	-9.6 (18.9)	-7.7 (19.3)	-12.9 (26.8)
	No (n/N)	112/223	113/225	116/229	116/228	116/229
	Mean Changes from baseline (SD)	2.9 (24.4)	-1.1 (23.7)	1.8 (19.1)	4.5 (21.3)	-1.6 (25.6)
	MCID (95% CI)	-10.2 (-16.5, -3.9)	-9.9 (-16.0, -3.8)	-11.4 (-16.3, -6.5)	-12.2 (-17.5, -6.9)	-11.3 (-18.1, -4.5)

Table S2. Minimal clinically important differences (MCIDs) in participants with mMRC 3-4

Dimension		Unpleasantness	Intensity			
Focal period		**Current**	**Current**	**Average**	**Best**	**Worst**
Participant preference question used						
I have been less breathless during the past week	Yes (n/N)	109/206	111/208	114/212	113/211	114/212
	Mean Changes from baseline (SD)	-7.0 (26.3)	-13.0 (24.0)	-7.7 (18.0)	-7.2 (19.6)	-11.7 (27.7)
	No (n/N)	97/206	97/208	98/212	98/211	98/212
	Mean Changes from baseline (SD)	3.7 (20.7)	1.5 (22.2)	1.0 (20.9)	5.5 (21.3)	-0.6 (24.5)
	MCID (95% CI)	-10.7 (-17.3, -4.1)	-14.5 (-20.9, -8.1)	-8.7 (-14.0, -3.4)	-12.7 (-18.3, -7.1)	-11.1 (-18.2, -4.0)
This medication would benefit me enough to be on it long term	Yes (n/N)	103/200	104/202	105/206	104/205	105/206
	Mean Changes from baseline (SD)	-7.0 (23.3)	-10.8 (22.9)	-9.3 (19.0)	-7.8 (19.4)	-12.7 (27.2)
	No (n/N)	97/200	98/202	101/206	101/205	101/206
	Mean Changes from baseline (SD)	3.1 (24.8)	-1.3 (25.0)	1.6 (19.7)	5.2 (21.8)	-1.3 (25.3)
	MCID (95% CI)	-10.1 (-16.8, -3.4)	-9.5 (-16.1, -2.9)	-10.9 (-16.2, -5.6)	-13.0 (-18.7, -7.3)	-11.4 (-18.6, -4.2)

MCIDs were calculated using two participant anchors (questions).

Table S3. Relative MCIDs (percentage change from baseline) calculated using two participant anchors

Dimension		Unpleasantness	Intensity			
Focal period		Current	Current	Average	Best	Worst
Participant preference question used						
I have been less breathless during the past week	Yes (n/N)	118/225	121/229	123/233	123/228	124/233
	Relative Changes from baseline (95% CI)	26.9% (-13.8%, 67.8%)	-17.2% (-28.3%, -6.1%)	-7.8% (-23.3%, 7.7%)	16.9% (-11.8%, 45.6%)	2.5% (-21.0%, 26.0%)
	No (n/N)	107/225	108/229	109/233	105/228	109/233
	Relative Changes from baseline (95% CI)	64.1% (23.4%, 104.6%)	28.9% (8.3%, 49.5%)	33.0% (10.0%, 56.0%)	80.4% (39.2%, 121.6%)	37.4% (-3.4%, 78.2%)
	Relative MCID (95% CI)	-37.0% (-94.4%, 20.4%)	-46.1% (-68.7%, -23.5%)	-40.8% (-67.8%, -13.8%)	-63.5% (-112.4%, 14.6%)	-34.9% (-80.4%, 10.6%)
This medication would benefit me enough to be on it long term	Yes (n/N)	110/220	112/224	112/227	111/223	113/228
	Relative Changes from baseline (95% CI)	-14.0% (-39.7%, 11.7%)	-13.8% (-26.7%, -0.8)	-11.6% (-27.9%, 4.7%)	5.2% (-18.9%, 29.3%)	-1.0% (-25.6%, 23.6%)
	No (n/N)	110/220	112/224	115/227	112/223	115/228
	Relative Changes from baseline (95% CI)	76.1% (23.5%, 128.5%)	23.5% (4.0%, 43.0%)	29.5% (4.0%, 55.0%)	78.7% (39.3%, 118.0%)	25.9% (-5.3%, 57.1%)
	Relative MCID (95% CI)	-90% (-148.1%, -31.8%)	-37.3% (-60.5%, -14.0%)	-41.1% (-71.4%, -10.8%)	-73.5% (-119.4%, -27.6%)	-26.9% (-66.5%, 12.7%)

The relative MCID was defined as the change in the score divided by the score at baseline.

Abbreviaions: MCID, minimal clinically important difference.